Abstract
Symptoms of urinary dysfunction occur frequently in patients with Parkinson’s disease (PD), particularly men. Irritative symptoms, such as frequency, urgency, and urge incontinence, are reported in 57–83% of patients with PD. Obstructive symptoms, such as hesitancy and weak urinary stream, may be present in 17–36% of individuals. The appearance of urinary symptoms may follow the appearance of motor symptoms by a few years. Several mechanisms, such as detrusor hyperreflexia, detrusor areflexia, coexistent obstructive uropathies, and dysfunction of infravesical mechanisms, can be responsible for the urinary dysfunction in patients with PD. Detrusor hyperreflexia is the urodynamic correlate of irritative urinary symptoms. Detrusor areflexia is uncommon in PD and, when present, is usually secondary to the use of anticholinergic medications. Coexistent obstructive uropathies may complicate the clinical picture in patients with PD and produce both obstructive and irritative symptoms. Urinary dysfunction in PD also may be the result of dysfunctional infravesical mechanisms such as sphincter bradykinesia. In terms of pathogenesis, voiding dysfunction in PD is primarily due to the loss of the inhibitory effect that the basal ganglia exert on the pontine micturition center. This inhibitory effect likely is mediated by D1 dopamine receptors and results in a “quiet bladder” during the filling phase. In terms of treatment, the irritative symptoms often can be treated successfully with anticholinergic drugs; however, for refractory overactive bladder, intravesical botulinum toxin injections or deep brain stimulation surgery may be required. If the symptoms are obstructive in nature, bladder catheterization and sometimes urological surgery may be necessary.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry. 2000;68(4):429–33.
Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho Jr RM, Ribeiro SC, de Carvalho DF. Urinary symptoms in Parkinson’s disease: prevalence and associated factors. Arq Neuropsiquiatr. 2003;61(2B):359–63.
Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson’s disease patients and normal controls. Parkinsonism Relat Disord. 2003;10(2):67–71.
Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson’s disease. Eur Neurol. 1992;32(3):134–40.
Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci. 2001;92(1–2):76–85.
Sammour ZM, Gomes CM, Barbosa ER, et al. Voiding dysfunction in patients with Parkinson’s disease: impact of neurological impairment and clinical parameters. Neurourol Urodyn. 2009;28(6):510–5.
Murnaghan GF. Neurogenic disorders of the bladder in Parkinsonism. Br J Urol. 1961;33:403–9.
Raz S. Parkinsonism and neurogenic bladder. Experimental and clinical observations. Urol Res. 1976;4(3):133–8.
Berger Y, Blaivas JG, DeLaRocha ER, Salinas JM. Urodynamic findings in Parkinson’s disease. J Urol. 1987;138(4):836–8.
Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson’s disease. J Urol. 1983;129(1):80–3.
Porter RW, Bors E. Neurogenic bladder in parkinsonism: effect of thalamotomy. J Neurosurg. 1971;34(1):27–32.
Niimi Y, Ieda T, Hirayama M, et al. Clinical and physiological characteristics of autonomic failure with Parkinson’s disease. Clin Auton Res. 1999;9(3):139–44.
Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol. 1997;80(1):100–4.
Raudino F. Non motor off in Parkinson’s disease. Acta Neurol Scand. 2001;104(5):312–5.
Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000;164(5):1640–3.
Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunction. J Neurol Sci. 2001;187(1–2):55–9.
Andersen JT. Disturbances of bladder and urethral function in Parkinson’s disease. Int Urol Nephrol. 1985;17(1):35–41.
Martignoni E, Pacchetti C, Godi L, Micieli G, Nappi G. Autonomic disorders in Parkinson’s disease. J Neural Transm Suppl. 1995;45:11–9.
Galloway NT. Urethral sphincter abnormalities in Parkinsonism. Br J Urol. 1983;55(6):691–3.
Fitzmaurice H, Fowler CJ, Rickards D, et al. Micturition disturbance in Parkinson’s disease. Br J Urol. 1985;57(6):652–6.
Stocchi F, Carbone A, Inghilleri M, et al. Urodynamic and neurophysiological evaluation in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 1997;62(5):507–11.
Andersen JT, Bradley WE. Cystometric, sphincter and electromyelographic abnormalities in Parkinson’s disease. J Urol. 1976;116(1):75–8.
Sotolongo Jr JR. Voiding dysfunction in Parkinson’s disease. Semin Neurol. 1988;8(2):166–9.
Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA. 1987;257(22):3076–81.
Andersen JT, Hebjorn S, Frimodt-Moller C, Walter S, Worm-Petersen J. Disturbances of micturition in Parkinson’s disease. Acta Neurol Scand. 1976;53(3):161–70.
Berger Y, Salinas JN, Blaivas JG. Urodynamic differentiation of Parkinson’s disease and Shy Dragger syndrome. Neurourol Urodyn. 1990;9:117–21.
Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet. 1988;2(8626–8627):1451–3.
Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson’s disease patients with the wearing-off phenomenon. Mov Disord. 2003;18(5):573–8.
Fowler CJ. Urinary disorders in Parkinson’s disease and multiple system atrophy. Funct Neurol. 2001;16(3):277–82.
Singer C, Weiner WJ, Sanchez-Ramos J, Ackerman M. Sexual function in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1991;54(10):942.
Eardley I, Quinn NP, Fowler CJ, et al. The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. Br J Urol. 1989;64(4):360–2.
Vodusek DB. Sphincter EMG and differential diagnosis of multiple system atrophy. Mov Disord. 2001;16(4):600–7.
Chancellor MB, Yoshimura N. Neurophysiology of stress urinary incontinence. Rev Urol. 2004;6 Suppl 3:S19–28.
Keane DP, O’Sullivan S. Urinary incontinence: anatomy, physiology and pathophysiology. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14(2):207–26.
Blok BF, Willemsen AT, Holstege G. A PET study on brain control of micturition in humans. Brain. 1997;120(Pt 1):111–21.
Nour S, Svarer C, Kristensen JK, Paulson OB, Law I. Cerebral activation during micturition in normal men. Brain. 2000;123(Pt 4):781–9.
Griffiths DJ. The pontine micturition centres. Scand J Urol Nephrol Suppl. 2002;(210):21–6.
Matsuura S, Kakizaki H, Mitsui T, Shiga T, Tamaki N, Koyanagi T. Human brain region response to distention or cold stimulation of the bladder: a positron emission tomography study. J Urol. 2002;168(5):2035–9.
Kavia RB, Dasgupta R, Fowler CJ. Functional imaging and the central control of the bladder. J Comp Neurol. 2005;493(1):27–32.
Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat Disord. 2009;15(2):81–7.
Lewin RJ, Dillard GV, Porter RW. Extrapyramidal inhibition of the urinary bladder. Brain Res. 1967;4(4):301–7.
Lewin RJ, Porter RW. Inhibition of spontaneous bladder activity by stimulation of the globus pallidus. Neurology. 1965;15(11):1049–52.
Athwal BS, Berkley KJ, Hussain I, et al. Brain responses to changes in bladder volume and urge to void in healthy men. Brain. 2001;124(Pt 2):369–77.
Kitta T, Kakizaki H, Furuno T, et al. Brain activation during detrusor overactivity in patients with Parkinson’s disease: a positron emission tomography study. J Urol. 2006;175(3 Pt 1):994–8.
Abramovicz M. Tolterodine for overactive bladder. Med Lett. 1998;40:101–3.
Siroky MB. Neurological disorders cerebrovascular disease and parkinsonism. Urol Clin North Am. 2003;30(1):27–47, v.
Abramovicz M. Oxybutynin transdermal (Oxytrol) for overactive bladder. Med Lett. 2003;45(1156):38–9.
Appell RA. Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent. Drugs. 2006;66(10):1361–70.
Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother. 2009;43(2):283–95.
Staskin DR, Rosenberg MT, Sand PK, Zinner NR, Dmochowski RR. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009;63(12):1715–23.
Giannantoni A, Mearini E, Del Zingaro M, Santaniello F, Porena M. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application. BJU Int. 2008;102 Suppl 1:2–6.
Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182(4):1453–7.
Finazzi-Agro E, Peppe A, D’Amico A, et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson’s disease. J Urol. 2003;169(4):1388–91.
Seif C, Herzog J, van der Horst C, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol. 2004;55(1):118–20.
Shimizu N, Matsumoto S, Mori Y, et al. Effects of deep brain stimulation on urodynamic findings in patients with Parkinson’s disease. Hinyokika Kiyo. 2007;53(9):609–12.
Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson’s disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord. 2007;22(2):220–5.
Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson’s disease. Brain. 2006;129(Pt 12):3366–75.
Edwards MJ, Talelli P, Rothwell JC. Clinical applications of transcranial magnetic stimulation in patients with movement disorders. Lancet Neurol. 2008;7(9):827–40.
Brusa L, Agro EF, Petta F, et al. Effects of inhibitory rTMS on bladder function in Parkinson’s disease patients. Mov Disord. 2009;24(3):445–8.
Kabay SC, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson’s disease. Neurourol Urodyn. 2009;28(1):62–7.
Vodusek DB, Light JK, Libby JM. Detrusor inhibition induced by stimulation of pudendal nerve afferents. Neurourol Urodyn. 1986;5:381–9.
Fall M, Lindstrom S. Electrical stimulation. A physiologic approach to the treatment of urinary incontinence. Urol Clin North Am. 1991;18(2):393–407.
Krivoborodov GG, Gekht AB, Korshunova ES. Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson’s disease. Urologiia. 2006;(4):3–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Moore, H., Singer, C. (2013). Urological Dysfunction. In: Pfeiffer, R.F., Bodis-Wollner, I. (eds) Parkinson’s Disease and Nonmotor Dysfunction. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-429-6_12
Download citation
DOI: https://doi.org/10.1007/978-1-60761-429-6_12
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-428-9
Online ISBN: 978-1-60761-429-6
eBook Packages: MedicineMedicine (R0)